Cargando…

B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients

BACKGROUND: The expression alterations of B4GALT1 have been noted in some types of cancer and they are related to cancer cell proliferation, invasiveness, metastasis, and drug resistance. We aimed to establish the expression of B4GALT1 in bladder cancer and its connection to patient outcomes, as wel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Huyang, Zhu, Yu, Zhang, Junyu, Liu, Zheng, Fu, Hangcheng, Cao, Yifan, Li, Gaoxiang, Shen, Yijun, Dai, Bo, Xu, Jiejie, Ye, Dingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968541/ https://www.ncbi.nlm.nih.gov/pubmed/29793447 http://dx.doi.org/10.1186/s12885-018-4497-0

Ejemplares similares

Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma
por: Xie, Huyang, et al.
Publicado: (2016)

Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma
por: Wang, Beihe, et al.
Publicado: (2017)

High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients
por: Fu, Hangcheng, et al.
Publicado: (2016)

Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer
por: Abudurexiti, MierXiati, et al.
Publicado: (2019)

Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma
por: Bo, Xiaobo, et al.
Publicado: (2017)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
por: Yan, Sen, et al.
Publicado: (2022)

Selective Generation of Gut Tropic T Cells in Gut-associated Lymphoid Tissue (GALT): Requirement for GALT Dendritic Cells and Adjuvant
por: Johansson-Lindbom, Bengt, et al.
Publicado: (2003)

Tumor-infiltrating IL-17A(+) cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer
por: Wang, Zewei, et al.
Publicado: (2020)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?
por: Tian, Junjie, et al.
Publicado: (2021)

Prognostic value of granulocyte colony-stimulating factor in patients with non-metastatic clear cell renal cell carcinoma
por: Liu, Zheng, et al.
Publicado: (2017)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma
por: Wang, Zewei, et al.
Publicado: (2016)

NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer
por: Wu, Junlong, et al.
Publicado: (2017)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2015)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2016)

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018)

Log Odds Could Better Predict Survival in Muscle-Invasive Bladder Cancer Patients Compared with pN and Lymph Node Ratio
por: Jin, Shengming, et al.
Publicado: (2019)

Tumor‐infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer
por: Wang, Jie, et al.
Publicado: (2018)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials
por: Kim, Hyung Suk, et al.
Publicado: (2017)

Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy
por: Pardo, Juan Carlos, et al.
Publicado: (2022)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
por: Sun, Jong-Mu, et al.
Publicado: (2012)

Adjuvant Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer
por: DRĂGOESCU, O., et al.
Publicado: (2014)

Clinical benefit to regionalization of care for muscle invasive bladder cancer
por: Haque, Waqar, et al.
Publicado: (2018)

Is there an oncological benefit to extended lymphadenectomy for muscle-invasive bladder cancer?
por: Clinton, Timothy N., et al.
Publicado: (2020)

B4GALT5 high expression associated with poor prognosis of hepatocellular carcinoma
por: Han, Yang, et al.
Publicado: (2022)

Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
por: Zeng, Han, et al.
Publicado: (2020)

Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin(+) cell abundance
por: Zhou, Quan, et al.
Publicado: (2020)

Two Hydroxyproline Galactosyltransferases, GALT5 and GALT2, Function in Arabinogalactan-Protein Glycosylation, Growth and Development in Arabidopsis
por: Basu, Debarati, et al.
Publicado: (2015)

Intratumoral CCR5(+) neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses
por: Xiang, Zhuoyi, et al.
Publicado: (2020)

Does Time to Adjuvant Chemotherapy after Radical Cystectomy Affect Survival in Muscle Invasive Bladder Cancer? A Systematic Review
por: Kronstedt, Shane, et al.
Publicado: (2022)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
por: Liu, David, et al.
Publicado: (2017)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n2ugnu8senuirgcch8pbrlnlkc